If there is one universal trait that all of humanity shares, it’s our love of pets.
Yet there still remains a vast innovation gap when it comes to cutting edge pharmaceutical treatments for animals.
Did you know that cancer is the leading cause of death for both dogs and cats?
With all the amazing pharmaceutical advancements made in recent years, it may come as a surprise that there still remains such a gap between human and veterinary sciences.
Animal Life Sciences is seeking to change that. They’re on a mission to take the advancements made in human treatments and leverage those breakthroughs for pet care.
Animal Life Sciences has obtained exclusive rights to license 10 major drugs in development for human care and tailor them for the pet care market.
The Future of Animal Life Sciences
Animal Life Sciences’ target market is two-fold. First they seek to target the pet medicine industry ($15B+), followed by a venture into pet food ($30B).
What Interested Investors Need to Know
Three things that investors should take note of:
- Bridging the innovation gap: They’re joining existing work in the areas of cancer treatment and tailoring it towards pets.
- One-two punch: joining veterinary science with pet food and supplements could be a lucrative combo.
- Show me the money: Targeting a combined $45B market.